PISCES Trial: The End Does Not Always Justify the Means

被引：2

作者：

Barni, Sandro ^{[1
]}

Petrelli, Fausto ^{[1
]}

机构：

[1] Azienda Osped Treviglio, Treviglio, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 33期

关键词：

RENAL-CELL CARCINOMA; 2ND-LINE TREATMENT; SUNITINIB; PAZOPANIB; SORAFENIB;

D O I：

10.1200/JCO.2014.56.8832

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

收藏

页码：3782 / 3782

页数：1

相关论文

共 7 条

[1]

BONADONNA G, 1995, JAMA-J AM MED ASSOC, V273, P542

[2]

Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study [J].

Escudier, Bernard ;

Porta, Camillo ;

Bono, Petri ;

Powles, Thomas ;

Eisen, Tim ;

Sternberg, Cora N. ;

Gschwend, Juergen E. ;

De Giorgi, Ugo ;

Parikh, Omi ;

Hawkins, Robert ;

Sevin, Emmanuel ;

Negrier, Sylvie ;

Khan, Sadya ;

Diaz, Jose ;

Redhu, Suman ;

Mehmud, Faisal ;

Cella, David .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (14) :1412-+

[3]

Pazopanib as Second-Line Treatment After Sunitinib or Bevacizumab in Patients With Advanced Renal Cell Carcinoma: A Sarah Cannon Oncology Research Consortium Phase II Trial [J].

Hainsworth, John D. ;

Rubin, Mark S. ;

Arrowsmith, Edward R. ;

Khatcheressian, James ;

Crane, Edward J. ;

Franco, Luis A. .

CLINICAL GENITOURINARY CANCER, 2013, 11 (03) :270-275

[4]

Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort [J].

Iacovelli, Roberto ;

Carteni, Giacomo ;

Sternberg, Cora N. ;

Milella, Michele ;

Santoni, Matteo ;

Di Lorenzo, Giuseppe ;

Ortega, Cinzia ;

Sabbatini, Roberto ;

Ricotta, Riccardo ;

Messina, Caterina ;

Lorusso, Vito ;

Atzori, Francesco ;

De Vincenzo, Fabio ;

Sacco, Cosimo ;

Boccardo, Francesco ;

Valduga, Francesco ;

Massari, Francesco ;

Baldazzi, Valentina ;

Cinieri, Saverio ;

Mosca, Alessandra ;

Ruggeri, Enzo Maria ;

Berruti, Alfredo ;

Cerbone, Linda ;

Procopio, Giuseppe .

EUROPEAN JOURNAL OF CANCER, 2013, 49 (09) :2134-2142

[5]

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma [J].

Motzer, Robert J. ;

Hutson, Thomas E. ;

Cella, David ;

Reeves, James ;

Hawkins, Robert ;

Guo, Jun ;

Nathan, Paul ;

Staehler, Michael ;

de Souza, Paul ;

Merchan, Jaime R. ;

Boleti, Ekaterini ;

Fife, Kate ;

Jin, Jie ;

Jones, Robert ;

Uemura, Hirotsugu ;

De Giorgi, Ugo ;

Harmenberg, Ulrika ;

Wang, Jinwan ;

Sternberg, Cora N. ;

Deen, Keith ;

McCann, Lauren ;

Hackshaw, Michelle D. ;

Crescenzo, Rocco ;

Pandite, Lini N. ;

Choueiri, Toni K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (08) :722-731

[6]

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial [J].

Motzer, Robert J. ;

Escudier, Bernard ;

Tomczak, Piotr ;

Hutson, Thomas E. ;

Michaelson, M. Dror ;

Negrier, Sylvie ;

Oudard, Stephane ;

Gore, Martin E. ;

Tarazi, Jamal ;

Hariharan, Subramanian ;

Chen, Connie ;

Rosbrook, Brad ;

Kim, Sinil ;

Rini, Brian I. .

LANCET ONCOLOGY, 2013, 14 (06) :552-562

[7]

A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma [J].

Stenner, Frank ;

Chastonay, Rahel ;

Liewen, Heike ;

Haile, Sarah R. ;

Cathomas, Richard ;

Rothermundt, Christian ;

Siciliano, Raffaele D. ;

Stoll, Susanna ;

Knuth, Alexander ;

Buchler, Tomas ;

Porta, Camillo ;

Renner, Christoph ;

Samaras, Panagiotis .

ONCOLOGY, 2012, 82 (06) :333-340